Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 256

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 256
---
 which Valent transferred to the Company all its right, title and interest in, and to, the patents for VAL-083owned by Valent. The Company now owns all rights and title to VAL-083and is responsible for further development and commercialization. In accordance with the terms of the Valent Assignment Agreement, Valent is entitled to receive a future royalty on all revenues derived from the development and commercialization of VAL-083.In the event that the Company terminates the agreement, the Company may be entitled to receive royalties from Valent’s subsequent development of VAL-083depending on the development milestones the Company has achieved prior to the termination of the Valent Assignment Agreement. On September 30, 2014, the Company entered into an exchange agreement (the “Valent Exchange Agreement”) with Valent and Del Mar (BC). Pursuant to the Valent Exchange Agreement, Valent exchanged its loan payable in the outstanding amount of $ 279(including aggregate accrued interest to September 30, 2014, of $ 29), issued to Valent by Del Mar (BC), for 279shares of the Company’s Series A Preferred Stock. The Series A Preferred Stock has a stated value of $ 1.00per share (the “Series A Stated Value”) and is not convertible into common stock. The holder of the Series A Preferred Stock is entitled to dividends at the rate of 3% of the Series A Stated Value per year, payable quarterly in arrears. For the year ended June 30, 2024, the Company recorded $ 8(2023 - $ 8 ) related to the dividends paid to Valent. The dividends have been recorded as a direct increase in accumulated deficit. On February 13, 2024, the Company sent an Opt-OutNotice to Valent under the Valent Assignment Agreement whereby the Company assigned all rights, title and interest in and to the patents for VAL-083to Valent. As a result, the Company granted Valent a non-exclusive,fully-paid, royalty-free, perpetual, worldwide and non-transferablelicense, subject to limited exceptions. The Company is entitled to receive royalties from Valent’s subsequent commercialization of VAL-083equal to 5% of Valent Net Sales (as defined in the Valent Assignment Agreement). Related party payables At June 30, 2024 there is an aggregate amount of $ 52(2023 - $ 298) payable to the Company’s officers and directors for fees, expenses, and accrued bonuses and other liabilities.

7. Milestone payment liability

The milestone payment liability